This kit uses T7 RNA polymerase to perform in vitro transcription of linear double-stranded DNA containing a T7 promoter sequence, with NTPs as substrates. The sequence downstream of the T7 promoter is transcribed, while the cap analog CAP GAG (ENE) is co-transcriptionally incorporated into the 5' end of the mRNA, generating single-stranded RNA with a 5'-m7G Cap1 structure. RNA with a Cap1 structure exhibits enhanced stability, thereby protecting the RNA from degradation in cells. This kit utilizes modified nucleotides (N1-me-Pseudo UTP) in place of conventional UTP. These modified nucleotides effectively reduce the immunogenicity of mRNA and suppress innate immune activation, resulting in in vitro transcribed mRNA with improved nuclease stability and translation efficiency. This makes the mRNA highly valuable for applications in medicine, therapeutics, and diagnostics.

A single reaction (20 μl system) using this kit can yield 120–160 μg of RNA product, and the system is scalable for high-level RNA production. The synthesized RNA can be used for in vitro translation, RNase protection assays, RNA splicing assay, and probe labeling, among other applications.

at -18˚C or below for one year

Dry ice (-70℃)